Engflag

Arflex Retard

Quick links to important sections

Arflex Retard

Arflex Retard_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arflex Retard

Property Description
Active ingredient Nimesulide
Form Prolonged-release tablet (Retard formulation)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of pain, inflammation, and fever
Origin Synthetic compound (methanesulfonamide derivative)

Arflex Retard is a prescription-only synthetic pharmaceutical preparation containing the active substance Nimesulide, which is broadly classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its core function is to provide relief by mitigating the complex biological pathways involved in pain, fever, and inflammation. The medicine's specific chemical identity is a methanesulfonamide derivative, placing it within the pyranilide chemical class.

What Type of Medicine is Arflex Retard?

Arflex Retard is a single-ingredient oral medication categorized within the NSAID group, known for its mechanism as a preferred cyclooxygenase-2 (COX-2) inhibitor. This pharmacological approach defines its action by selectively targeting the enzyme primarily responsible for the generation of inflammatory signals, distinguishing it from non-selective NSAIDs. Nimesulide is indicated for symptomatic relief in cases of acute pain and inflammation, reflecting its focused therapeutic application.

Nimesulide Composition and Prolonged-Release Formulation

The sole active component is Nimesulide, which is manufactured as a prolonged-release tablet, commercially termed a Retard formulation. This is a specialized sustained-release dosage form intended for oral administration. The Retard design is a key differentiating feature, as it ensures the active substance is released slowly and in a controlled manner over an extended period. This mechanism is critical because it aims to provide consistent therapeutic presence, supporting lasting relief throughout the dosing interval.

General Purpose and Mechanism of Relief

The general purpose of Arflex Retard is to provide symptomatic relief by addressing the primary elements of the inflammatory state: pain, fever, and inflammation. Nimesulide achieves this effect by interrupting the synthesis of prostaglandins, which act as key chemical messengers that stimulate pain receptors and regulate inflammatory processes. Nimesulide is utilized in the treatment of acute painful conditions and is characterized by its rapid onset of action alongside its sustained-release profile.

What side effects are possible with Arflex Retard?

Arflex Retard, which contains diclofenac sodium (an NSAID), is associated with a defined risk profile, focusing on gastrointestinal, cardiovascular, and hepatic adverse effects as documented by regulatory authorities.

Serious and Clinically Significant Risks

  • Cardiovascular Thrombotic Events: Use of diclofenac is associated with an increased risk of serious, potentially fatal, arteriothrombotic events, including myocardial infarction and stroke. This risk can increase with higher doses and prolonged use. The drug is generally contraindicated in patients with established congestive heart failure (NYHA II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Gastrointestinal (GI) Toxicity: Serious GI events, such as bleeding, ulceration, and perforation of the stomach or intestines, can occur without warning and may be fatal. Elderly patients and those with a prior history of GI disease are at greater risk.
  • Hepatotoxicity: Rare but serious hepatic reactions, including liver necrosis and fatal fulminant hepatitis, have been reported. Liver function should be monitored during long-term therapy.

Common Adverse Reactions

Common adverse effects, typically affecting the Gastrointestinal system (System-Organ Class), often include abdominal pain, nausea, dyspepsia, and headache. These are classified according to regulatory frequency bands (e.g., Common, Uncommon, Rare).

Population-Specific Safety Considerations

  • Pregnancy: Use in the third trimester is contraindicated due to the risk of premature closure of the fetal ductus arteriosus and fetal renal dysfunction.
  • Geriatric Patients: Older individuals are at a higher risk for serious GI adverse events and often require careful monitoring.

To minimize risks, regulatory bodies advise using the lowest effective dose for the shortest duration necessary for symptomatic relief.

Overdose and Emergency Response

Overdose and when to seek help

This information is based strictly on regulatory documents for Arflex Retard (Aceclofenac).

Documented Overdose Manifestations

An overdose may initially present with common signs such as nausea, vomiting, headache, drowsiness, and epigastric pain. Less frequently, gastrointestinal irritation or diarrhea may occur.

Serious or Life-Threatening Outcomes

Severe manifestations, particularly after significant ingestion, can involve multiple organ systems and may include gastrointestinal bleeding, acute renal failure, liver damage, hypotension, respiratory depression, and Central Nervous System effects such as disorientation, convulsions, or coma.

Emergency Actions and Seeking Urgent Help

Medical help should be sought immediately following any confirmed or suspected overdose. Management is primarily symptomatic and supportive, as no specific antidote is listed. Regulatory guidance notes that procedures like gastric lavage or administration of activated charcoal should be considered by medical professionals within one hour of a potentially toxic ingestion. Because Aceclofenac is highly protein-bound, elimination methods like dialysis are generally considered ineffective.

Therapeutic Uses of Arflex Retard

The therapeutic utility of Arflex Retard, containing Nimesulide, is centered on providing supportive relief for symptoms related to inflammatory and painful conditions. The medicine is generally applied in settings characterized by acute, short-term episodes.

Arflex Retard is commonly used to help with symptoms related to physical discomfort and inflammatory or irritative states. The medicine is applied in clinical settings that involve acute or unstable symptom patterns, such as managing pain and functional strain in episodes like acute tendinitis, short-term acute low back pain, and the disruptive manifestations of primary dysmenorrhoea (menstrual pain). It also plays a role in managing systemic fever that is often associated with these acute inflammatory changes.

“The primary goal is to contribute to easing the overall symptom load and supporting patients during episodes of heightened discomfort.”

The medication is relevant in clinical scenarios where symptoms become temporarily overwhelming, such as discomfort following minor surgical procedures. By addressing the symptomatic burden, the treatment may assist with supporting functional stability during these phases.

Quick Fact: Relief for Painful Episodes The design is relevant for managing symptoms that require consistent supportive relief, which may contribute to improved day-to-day comfort.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Arflex Retard

This section outlines the official population eligibility and non-eligibility for Arflex Retard (Nimesulide) as defined by authoritative regulatory documents.

Eligibility Scope

Classification Eligible Groups/Status
Allowed Adults and Adolescents from 12 years of age.
Not Recommended Women attempting to conceive or during the first two trimesters of pregnancy.

Absolute Contraindications (Must Not Use)

Arflex Retard is absolutely contraindicated (prohibited) for use in the following populations or conditions:

  • Children under 12 years of age.
  • Patients with hepatic impairment (liver dysfunction) or a history of hepatotoxic reactions to Nimesulide.
  • Patients with severe renal impairment (creatinine clearance < 30 ml/min) or severe heart failure.
  • Patients with an active peptic ulcer, active gastrointestinal bleeding, or a history of recurrent ulcers/bleeding.
  • Patients with severe coagulation disorders or other active bleeding (e.g., cerebrovascular bleeding).
  • Women during the third trimester of pregnancy or who are breastfeeding (lactation).
  • Patients with a known hypersensitivity to Nimesulide, excipients, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Conditional Use and Restrictions

Use requires special caution and monitoring for elderly patients and individuals with mild to moderate renal or cardiac impairment. These groups must use the medicine under restricted conditions, as advised by regulatory labeling.

What should I know about interactions with other medicines?

Arflex Retard, which contains the non-steroidal anti-inflammatory drug (NSAID) Nimesulide, can interact with several other medicinal products, requiring careful clinical management. Concomitant use with other NSAIDs (including aspirin or selective COX-2 inhibitors) is generally advised against due to a compounded risk of gastrointestinal adverse effects and bleeding.

This product may potentiate the effects of anticoagulants (such as warfarin) and antiplatelet agents, significantly increasing the risk of hemorrhage; patients must be closely monitored for altered coagulation parameters. The anti-hypertensive and diuretic effects of certain medicines, including diuretics and ACE inhibitors, may be diminished when taken with Nimesulide, and this combination also carries an increased risk of renal impairment.

Nimesulide can increase the concentration and toxicity of medicines cleared by the kidneys, such as Lithium and Methotrexate. Other interacting agents include cyclosporine, tolbutamide, fenitoin, and various antidepressants (like SSRIs). Patients should ensure all current medications are reviewed before use to manage potential dose adjustments and necessary clinical monitoring.

Mechanism of Action

The pharmacodynamic action of Arflex Retard is mediated by its active component, nimesulide, a non-steroidal anti-inflammatory drug (NSAID).

Its primary biological target is the cyclooxygenase-2 (COX-2) enzyme, to which it binds and acts as an inhibitor. This interaction restricts the conversion of arachidonic acid into prostaglandin H2 (PGH2), thereby disrupting the initial step of the prostanoid synthesis pathway. By suppressing COX-2 activity, nimesulide specifically decreases the production of pro-inflammatory prostaglandins, such as prostaglandin E2 (PGE2), in local tissues.

At the cellular level, this inhibition leads to a reduction in the concentration of PGE2, which typically acts on peripheral sensory neurons and central thermoregulatory centers. Furthermore, nimesulide modulates other inflammatory pathways, including the inhibition of metalloproteinases and the suppression of certain pro-inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFalpha).

System-level physiological consequences involve modulation of the peripheral nociceptive signaling and central regulation of body temperature.

Dosage and Administration Information

Administration Guidelines for Arflex Retard

This section outlines the procedural steps for administering Arflex Retard.

Entity Instructional Guidance
Route of Administration Oral (by mouth)
Dosing Schedule The standard adult dose, typically [Specific Strength, e.g., 200 mg], is administered once daily (Q.D.). This frequency is based on the extended-release formulation.
Timing in Relation to Meals Should be taken with food or immediately after a meal to help minimize potential gastrointestinal discomfort.
Special Procedural Conditions The extended-release capsule or tablet must be swallowed whole. It is explicitly prohibited to crush, cut, or chew the medication. Modifying the dosage form will destroy the extended-release properties and may lead to an unsafe concentration of the drug (dose dumping).

Procedural and Population-Specific Rules

Age-Group Administration Rules:

  • Geriatric Patients: A lower starting dose may be required. Dosage must be closely monitored and adjusted based on the patient's individual clinical status and tolerance.

Missed-Dose Rules:

  • If a dose is missed, do not take a double dose to compensate. The patient should take the next dose at the regularly scheduled time and continue the regimen as usual.

These instructions define the standardized, non-modified intake method for the extended-release oral dosage form. Adherence to swallowing the medicine whole and maintaining the once-daily schedule is essential for following the prescribed use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Arflex Retard

The available research concerning Arflex Retard is summarized here, focusing only on the structure of the evidence and what has been studied so far. This information is purely descriptive and does not offer clinical advice or prediction of individual outcomes.

Evidence for Use in Osteoarthritis (OA)

Arflex Retard was studied for use in adults diagnosed with osteoarthritis, a condition characterized by functional limitations and perceived discomfort. Research examined the outcomes related to short-term symptom patterns in Randomized Controlled Trials (RCTs) and subsequent analyses. These trials most often involved populations with mild-to-moderate pain severity.

Researchers primarily monitored outcomes related to physical discomfort and physical function assessments, such as the WOMAC index, over defined time intervals. The findings describe patterns observed in the studies during the short-term research period. However, limited evidence exists for populations with severe osteoarthritis, and limited information for long-term outcomes exists beyond one year.

Evidence for Use in Rheumatoid Arthritis (RA)

The product was studied for use in controlled trials involving adults with active Rheumatoid Arthritis (RA). Research scenarios involved comparing the product against a placebo or an active comparator. Studies examined the outcomes related to systemic or functional imbalance, specifically monitoring the count of swollen and tender joints and studies explored standard measures of disease activity. The data show patterns related to changes measured during the study period. Comparative evidence is lacking with many current treatments, and existing studies provide limited information regarding long-term radiological outcomes.

What Is Still Uncertain About Arflex Retard

Key areas of uncertainty exist. Follow-up durations were limited, and sample sizes were modest in some trials, meaning that small patterns of change may be difficult to characterize reliably. Evidence highlights what is known—and what is still uncertain, emphasizing that research is ongoing and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Arflex Retard (FAQ)

Q: What is the difference between Arflex Retard and regular Arflex?

A: Arflex Retard is a pharmaceutical designation for a prolonged-release dosage form containing the active ingredient Nimesulide. This 'Retard' design means the medicine is formulated to release the active substance slowly and continuously over an extended period. The official product information focuses on this sustained-release format, and information about a 'regular' or immediate-release version would depend on its specific regulatory authorization.

Q: Does Arflex Retard cure the underlying condition, or just manage symptoms?

A: According to official product information, the purpose of Arflex Retard (Nimesulide) is to provide symptomatic relief for conditions such as acute pain and primary dysmenorrhoea. It acts to manage the symptoms of pain, fever, and inflammation. Regulatory documents indicate that the medicine does not cure or modify the underlying progression of the disease.

Q: How long does it typically take to start feeling the effects of Arflex Retard?

A: Regulatory documents indicate a relatively rapid onset of action for the active substance Nimesulide. This initial relief is then followed by the sustained-release action of the Retard formulation, which works to maintain therapeutic presence over time. The experience of onset time can vary between individuals.

Q: Is it normal to experience a change in appetite while taking Arflex Retard?

A: Official regulatory documents list a specific change in appetite (anorexia) as a potential adverse reaction, typically classified as uncommon or rare. More commonly reported adverse reactions involve the gastrointestinal system, such as nausea or diarrhoea.

Q: Are there any known issues with taking Arflex Retard with common over-the-counter pain relievers?

A: Official information advises against the co-administration of Arflex Retard (Nimesulide) with other NSAIDs (including many OTC pain relievers) because it can increase the risk of gastrointestinal adverse effects and bleeding. Caution is also advised when combining it with other medicines known to affect the liver, such as paracetamol/acetaminophen.

Q: Is it possible for Arflex Retard to cause difficulty sleeping?

A: Regulatory documents list adverse reactions affecting the central nervous system. Difficulty sleeping (insomnia or sleep disorder) is described in official documentation, often classified within the uncommon frequency category.

Q: Is Arflex Retard safe for use in older adults?

A: Regulatory bodies advise that use in older adults requires special caution and monitoring. Geriatric patients may have an increased risk of NSAID-related adverse reactions, especially those affecting the stomach and intestines. Official guidelines suggest that a lower starting dose may be required. Decisions regarding dosage and monitoring are made by a healthcare provider based on the patient's individual condition.

Q: Are there any specific foods or drinks that should be avoided when using Arflex Retard?

A: Official documentation strongly advises patients to avoid excessive alcohol consumption during treatment with Nimesulide. This warning is based on the fact that alcohol may increase the risk of liver toxicity and potentially contribute to other side effects of the medicine.

Q: Does taking Arflex Retard affect the ability to drive or operate machinery?

A: Official documents state that Arflex Retard may cause certain central nervous system side effects, such as dizziness, drowsiness, or vertigo. Regulatory documents state that if these effects are experienced, individuals should avoid activities requiring alertness, such as driving or operating machinery.

Q: Are there published studies supporting the use of Arflex Retard in juvenile patients?

A: Regulatory documents restrict the authorized use of Arflex Retard (Nimesulide) to adolescents aged 12 years and older, for specific, time-limited indications. It is explicitly contraindicated (prohibited) for children under 12 years of age, which determines the scope of evidence and allowed use.

Q: What is the typical duration of effect for a single use of Arflex Retard?

A: Arflex Retard is formulated for once-daily administration. The prolonged-release mechanism is specifically designed to release the active substance over a 24-hour period to provide consistent relief until the next scheduled intake.

Q: Are headaches a common side effect described in the official documents for Arflex Retard?

A: Yes, headache is listed in official regulatory documentation as an adverse reaction that is classified as common. This means it may affect up to 1 in 10 patients using the medicine.

Q: Is Arflex Retard the same type of medicine as ibuprofen or naproxen?

A: Arflex Retard (Nimesulide) belongs to the same general class of medicines, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), that includes ibuprofen and naproxen. However, Nimesulide is specifically classified as a preferred COX-2 inhibitor, which distinguishes its primary mechanism of action by selectively targeting the enzyme that drives inflammatory signals.

Q: Does Arflex Retard have a risk of dependence or addiction?

A: Arflex Retard (Nimesulide) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Unlike some pain relief medications, regulatory product information and safety reviews do not list drug dependence, tolerance, or addiction as an identified risk or adverse reaction associated with its use.

Q: What is the difference between the active ingredient in Arflex Retard and other medicines for arthritis?

A: The active ingredient in Arflex Retard is Nimesulide, which is a methanesulfonamide derivative. This unique chemical structure makes it chemically and pharmacologically distinct from the active ingredients in other arthritis medicines, such as diclofenac, celecoxib, or traditional disease-modifying anti-rheumatic drugs (DMARDs).

Q: Can taking Arflex Retard affect the results of certain lab tests?

A: Official product information notes that use of Nimesulide is associated with a risk of elevations in liver enzymes (transaminases). These changes can be detected during routine liver function tests and, if significant, may require discontinuation of the medicine.

Q: Why might a doctor switch a patient from a different pain medicine to Arflex Retard?

A: Official EMA guidance often restricts the use of systemic Nimesulide to second-line treatment for specific acute pain conditions. This means a healthcare provider might consider it only when initial treatments (first-line) have been unsuccessful or are inappropriate for the patient.

Q: Are there any warnings about using Arflex Retard right before or after surgery?

A: Regulatory documents caution that Arflex Retard (Nimesulide) may interfere with platelet function, increasing the risk of bleeding. The medicine is generally contraindicated in patients with active bleeding or severe coagulation disorders, which requires careful consideration immediately before or after major surgical procedures.

Q: What is the significance of the 'Retard' formulation for reducing side effects?

A: The 'Retard' (prolonged-release) formulation is primarily designed to maintain consistent drug levels over a 24-hour period, which supports once-daily dosing. By avoiding high peak concentrations, the formulation's design may be associated with a reduced likelihood of certain peak-concentration-related adverse effects compared to immediate-release forms.

Q: Do studies suggest any potential benefit of Arflex Retard for muscle spasms?

A: The officially approved therapeutic indications for Arflex Retard (Nimesulide) are restricted to the treatment of acute pain and primary dysmenorrhoea. It is not officially indicated or studied for the specific treatment of muscle spasms.

Q: Is there a recommended 'washout' period if switching from another medicine to Arflex Retard?

A: Regulatory information does not define a universal 'washout' period. However, it strongly advises against the simultaneous use of Arflex Retard with other NSAIDs and interacting medicines. Regulatory guidance suggests a need to discontinue one medicine before initiating the other to prevent a combined or additive effect.

Q: How often do official sources recommend follow-up with a doctor while using Arflex Retard?

A: Official documentation requires careful clinical monitoring for specific risk groups, such as the elderly and those with mild heart or kidney impairment. It also mandates the monitoring of liver function during long-term therapy, indicating that the need for and frequency of follow-up is conditional on the patient’s individual risk factors and duration of use.

Q: Are there official descriptions of how Arflex Retard might affect blood pressure?

A: Regulatory documents note that Arflex Retard (Nimesulide) may diminish the anti-hypertensive and diuretic effects of certain blood pressure medications (like ACE inhibitors and diuretics). It is also advised that the medicine should be used with caution in patients with uncontrolled hypertension.

Q: What happens if a person occasionally misses a scheduled use of Arflex Retard?

A: The official instruction for a missed dose is to not take a double dose to make up for the forgotten one. The patient should simply take the next dose at the regularly scheduled time.

Q: Does the medicine start working immediately, or does it build up over time?

A: The active ingredient, Nimesulide, is described as having a relatively rapid onset of action for immediate relief. However, the prolonged-release ('Retard') formulation is specifically designed to maintain a consistent therapeutic concentration over time with daily use, which is a form of 'build-up' or steady state.

How should Arflex Retard be stored and disposed of?

Storage and Handling Requirements

Arflex Retard (Nimesulide prolonged-release tablets) must be stored in compliance with regulatory mandates to maintain its stability. The product should not be stored above 30°C and must remain in the original container to protect the integrity of the prolonged-release formulation from environmental factors.

As a prescription medication, Arflex Retard must be kept out of the sight and reach of children as a mandatory safety measure.

Official Disposal Rules

Unused or expired Arflex Retard must not be disposed of using household trash or by pouring it down a sink or toilet. Official disposal instructions require the medicine to be discarded through an authorized drug take-back program or managed according to local pharmaceutical waste regulations. This process is necessary to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Arflex Retard found in:

A-Z Index: